Reduces Binge Eating of Both Fat-Rich and Sugar-Rich Foods
This combination pharmacotherapy suppresses binge eating of both fat-rich and sugar-rich palatable foods without affecting normal food intake. More than 78 million U.S. adults are obese and 7 million U.S. adults suffer from binge eating disorder (BED), with the numbers rising annually. Available therapies successfully suppress binge eating of fat-rich but not sugar-rich foods. However, the majority of foods that are consumed in excess, thereby promoting obesity, are sugar rich or highly-palatable combinations of sugar and fat. Therefore, a therapy that only decreases binge eating of fat-rich foods is not fully effective. Researchers at the University of Florida have developed a combination pharmacotherapy – the GABA agonist, baclofen, concurrently given with the opioid antagonist, naltrexone – to decrease binge eating of both fat-rich and sugar-rich foods without affecting normal food intake. This treatment is intended for individuals who are overweight or obese, have a binge eating disorder, or a food addiction.
Baclofen/naltrexone combination pharmacotherapy treats obesity, binge eating disorder and food addiction by suppressing overeating of both fat-rich and sugar-rich foods
- Uses two safe, FDA-approved medications, reducing health risks
- Suppresses binge eating better than baclofen alone, increasing efficacy of obesity treatment
This combination treatment is composed of a mu-opioid receptor antagonist, naltrexone, and a GABA B receptor agonist, baclofen. Concurrent use of these two compounds reduces binge intake of both sugar-rich and fat-rich foods. Baclofen reduces overeating of fat-rich foods, while naltrexone reduces binge eating of sugar-rich foods. This combination pharmacotherapy can be a useful tool in reducing pleasurable eating and overeating with no apparent effect on normal food intake.